JP5698395B2 - Crystal and pharmaceutical preparation containing the crystal - Google Patents
Crystal and pharmaceutical preparation containing the crystal Download PDFInfo
- Publication number
- JP5698395B2 JP5698395B2 JP2014029418A JP2014029418A JP5698395B2 JP 5698395 B2 JP5698395 B2 JP 5698395B2 JP 2014029418 A JP2014029418 A JP 2014029418A JP 2014029418 A JP2014029418 A JP 2014029418A JP 5698395 B2 JP5698395 B2 JP 5698395B2
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- luliconazole
- alcohol
- reference example
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims description 118
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 claims description 44
- 229960000570 luliconazole Drugs 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 15
- 229940088679 drug related substance Drugs 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 85
- 238000001953 recrystallisation Methods 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 208000002474 Tinea Diseases 0.000 description 6
- 238000007664 blowing Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 208000010195 Onychomycosis Diseases 0.000 description 5
- 241000224526 Trichomonas Species 0.000 description 5
- 241000893966 Trichophyton verrucosum Species 0.000 description 5
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 201000005882 tinea unguium Diseases 0.000 description 5
- 208000007163 Dermatomycoses Diseases 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 201000003929 dermatomycosis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 208000035415 Reinfection Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 238000012982 x-ray structure analysis Methods 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- FETBSFKKXIIELW-MGVPTMGJSA-N CC(C1)N=CN1/C(/C#N)=C(/SC1)\S[C@@H]1c(c(Cl)c1)ccc1Cl Chemical compound CC(C1)N=CN1/C(/C#N)=C(/SC1)\S[C@@H]1c(c(Cl)c1)ccc1Cl FETBSFKKXIIELW-MGVPTMGJSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- GQFHZMYGRXRAHM-REQDGWNSSA-N N#C/C(/[n]1cncc1)=C(/SC1)\S[C@@H]1C(CCC(Cl)=C1)=C1Cl Chemical compound N#C/C(/[n]1cncc1)=C(/SC1)\S[C@@H]1C(CCC(Cl)=C1)=C1Cl GQFHZMYGRXRAHM-REQDGWNSSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000008710 crystal-8 Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Description
本発明は、ルリコナゾールの結晶及び該結晶を含有してなる医薬製剤に関する。 The present invention relates to crystals of luliconazole and pharmaceutical preparations containing the crystals.
ルリコナゾールは、下記に示す構造を有する、真菌に対する作用に優れる抗真菌剤であり、現在足白癬、体部白癬に対する医薬として広く使われ、爪白癬に対する作用にも応用されようとしている。ルリコナゾールの製剤には、ＳＥ体あるいはＺ体等への立体異性化、塗布直後における結晶析出などが解決されるべき問題として知られている（例えば、特許文献１、特許文献２、特許文献３，特許文献４、特許文献５、特許文献６を参照）。この内、異性化においては、ＳＥ体についても、Ｚ体についても、製剤成分の影響、温度の影響、或いは光の影響を受けることを本発明者らは確認している。その様な状況を反映して、ルリコナゾールの安定性の評価には、６０℃で３週間の保存条件が用いられている。斯くの如くに、ルリコナゾールの製造においては、加熱工程をなるべく短くする必要性があった。その一方で、ルリコナゾールは水溶性が低く、製剤成分に可溶化させるに際しても、加熱工程が必要であり、ルリコナゾールの溶解度を改善し、該加熱工程における加熱時間を短縮する手段の開発が求められていた。加熱工程の短縮は、この工程で生じる異性体の発生を抑制するばかりでなく、異性体量の初期値を低くすることで長期安定性も確保できるメリットを有している。言い換えれば、溶解工程の短縮は品質の大きな向上のつながると言える。 Luliconazole is an antifungal agent having the following structure and excellent in action against fungi, and is currently widely used as a medicine for tinea pedis and body tinea, and is also being applied to the action against tinea unguium. In the formulation of luliconazole, it is known that problems such as stereoisomerization into SE form or Z form, crystal precipitation immediately after coating, etc. should be solved (for example, Patent Document 1, Patent Document 2, Patent Document 3, (See Patent Literature 4, Patent Literature 5, and Patent Literature 6). Among these, in the isomerization, the present inventors have confirmed that both the SE form and the Z form are affected by the effects of the formulation components, the temperature, or the light. Reflecting such a situation, storage conditions of 3 weeks at 60 ° C. are used for evaluating the stability of luliconazole. As described above, in the production of luliconazole, it was necessary to shorten the heating step as much as possible. On the other hand, luliconazole has low water solubility and requires a heating step when solubilized in formulation components, and there is a need to develop means for improving the solubility of luliconazole and shortening the heating time in the heating step. It was. The shortening of the heating step not only suppresses the generation of isomers generated in this step, but also has an advantage that long-term stability can be secured by lowering the initial value of the isomer amount. In other words, shortening the dissolution process can lead to a significant improvement in quality.
ルリコナゾールの原体は、酢酸エチルとｎ−ヘキサンから再結晶して製造される方法が知られている（例えば、特許文献７を参照）が、アルコールでの再結晶或いは、原体にアルコールを添加する様な工程については全く知られていない。従って、短鎖長アルコールを含有する結晶や医薬原体用の組成物については、全く何も知られていないのが現状であると言える。 It is known that the raw material of luliconazole is produced by recrystallization from ethyl acetate and n-hexane (see, for example, Patent Document 7), but recrystallization with alcohol or addition of alcohol to the raw material. There is no known process for doing this. Therefore, it can be said that nothing is known about the composition containing a short-chain alcohol and a composition for a drug substance.
本発明は、この様な状況下為されたものであり、製剤の安定性を向上すべく、ルリコナゾールの溶解性を改善する手段を提供することを課題とする。 The present invention has been made under such circumstances, and an object thereof is to provide means for improving the solubility of luliconazole in order to improve the stability of the preparation.
この様な状況に鑑みて、本発明者らは、製剤の安定性を向上すべく、ルリコナゾールの溶解性を改善する手段を求めて、鋭意研究努力を重ねた結果、短鎖長アルコールを含有した結晶及び医薬原体用の組成物が、その様な特性を有していることを見出し、発明を完成させるに至った。即ち、本発明の要旨は、以下に示す通りである。 In view of such a situation, the present inventors have sought for means for improving the solubility of luliconazole in order to improve the stability of the preparation, and as a result of earnest research efforts, the present inventors have contained a short-chain alcohol. It has been found that compositions for crystals and drug substances have such properties, and the present invention has been completed. That is, the gist of the present invention is as follows.
＜１＞下記に示すルリコナゾールと、メタノールからなる結晶。 <1> A crystal comprising luliconazole shown below and methanol.
＜２＞前記メタノールの含有量は、結晶全量に対して、１００〜１０，０００ｐｐｍである、＜１＞に記載の結晶。
＜３＞水を含んでいてもよいメタノールで再結晶し、乾燥させて、所望により、メタノールを添加して、製造される、＜１＞又は＜２＞に記載の結晶。
＜４＞＜１＞〜＜３＞の何れかに記載の結晶を含む、医薬原体用の組成物。
＜５＞＜４＞に記載の医薬原体用の組成物を配合してなる、医薬製剤。
＜６＞＜１＞〜＜３＞の何れかに記載の結晶又は＜４＞に記載の医薬原体用の組成物を溶剤へ溶解する工程を含む、医薬製剤の製造方法。
＜７＞＜６＞に記載の製造方法により製造された、医薬製剤。
<2> The crystal according to <1>, wherein the methanol content is 100 to 10,000 ppm with respect to the total amount of the crystal.
<3> The crystal according to <1> or <2>, which is produced by recrystallization with methanol which may contain water, drying, and optionally adding methanol.
<4> A composition for a drug substance comprising the crystal according to any one of <1> to <3>.
<5> A pharmaceutical preparation comprising the composition for a drug substance according to <4>.
<6> A method for producing a pharmaceutical preparation, comprising a step of dissolving the crystal according to any one of <1> to <3> or the composition for a drug substance according to <4> in a solvent.
<7> A pharmaceutical preparation produced by the production method according to <6>.
本発明によれば、ルリコナゾールの溶解性を改善する手段を提供することができる。 According to the present invention, a means for improving the solubility of luliconazole can be provided.
＜１＞本発明の結晶
本発明の結晶は、ルリコナゾールと短鎖長アルコールとを含有することを特徴とする。本発明の結晶は、ルリコナゾールと短鎖長アルコールとを含有する結晶複合体、又はルリコナゾールと短鎖長アルコールとを含有する結晶マトリックスと言い換えることもできる。本明細書において、これらの用語は同義で用いられ、いずれも本発明の範囲内である。
前記短鎖長アルコールとしては、例えば、メタノール、エタノール、イソプロピルアルコール、ブタノールのような炭素数１〜４の直鎖又は側鎖を有するアルコール［メタノール、エタノール、１−プロパノール（プロピルアルコール）、２−プロパノール（イソプロピルアルコール）、１−ブタノール（ｎ−ブチルアルコール）、２−ブタノール（sec-ブチルアルコール）、２−メチル−１−プロパノール（イソブチルアルコール）、２-メ
チル−２−プロパノール（tert-ブチルアルコール）等］が好ましく例示でき、特に、メ
タノールが好ましい。結晶が、これらのアルコールから選ばれる２種以上を含有してもよい。かかる短鎖長のアルコールの含有量は、結晶全質量に対して、１００〜１０，０００ｐｐｍが好ましく、より好ましくは５００〜５，０００ｐｐｍである。これは、少なすぎると、溶解性向上効果を奏さない場合が存し、多すぎると結晶全体の安定性を損なう場合があるためである。ルリコナゾールの含有量は、結晶の全質量に対して９５質量％以上であることが好ましく、より好ましくは９９質量％以上である。
<1> Crystal of the Present Invention The crystal of the present invention is characterized by containing luliconazole and a short chain length alcohol. The crystal of the present invention can also be referred to as a crystal complex containing luliconazole and a short chain length alcohol, or a crystal matrix containing luliconazole and a short chain length alcohol. In the present specification, these terms are used synonymously and are all within the scope of the present invention.
Examples of the short chain long alcohol include alcohols having a straight chain or a side chain having 1 to 4 carbon atoms such as methanol, ethanol, isopropyl alcohol, and butanol [methanol, ethanol, 1-propanol (propyl alcohol), 2- Propanol (isopropyl alcohol), 1-butanol (n-butyl alcohol), 2-butanol (sec-butyl alcohol), 2-methyl-1-propanol (isobutyl alcohol), 2-methyl-2-propanol (tert-butyl alcohol) ) Etc.] is preferable, and methanol is particularly preferable. The crystal may contain two or more selected from these alcohols. The content of such a short chain alcohol is preferably 100 to 10,000 ppm, more preferably 500 to 5,000 ppm, based on the total mass of the crystal. This is because if the amount is too small, the effect of improving the solubility may not be achieved, and if the amount is too large, the stability of the entire crystal may be impaired. The content of luliconazole is preferably 95% by mass or more, more preferably 99% by mass or more, based on the total mass of the crystal.
この様な結晶は、例えば、ルリコナゾールを、水を含んでもよい短鎖長アルコールを用いて再結晶し、濾取した後、送風乾燥し、短鎖長のアルコール量を計測し、短鎖長アルコール量が好ましい範囲になかった場合には、短鎖長アルコールを添加するなど、所望により、短鎖長アルコールを含有せしめて製造することができる。また、短鎖長アルコールが多すぎる場合には、更に、送風乾燥させて調整することもできる。
再結晶としては、含水アルコールで再結晶してもよいし、水を貧溶媒として用いてもよい。貧溶媒法は、ルリコナゾールを含むアルコール溶液に、析出に十分な量の水を加える方法である。好ましい形態としては１０％含水アルコールで再結晶することが、最終的な純度の面で好ましい。
再結晶化は、通常の再結晶化手法に従って行うことができる。
かかるアルコールは使用時に水とともに用いても、或いは、予め含水させた状態で用いても良く、ともに用いることの出来る水の量としては、水を含んでもよいアルコール全量に対して、例えば９〜８０％、３０〜８０％、５０〜７５％、最大７０％程度が好ましく例示できる。
Such crystals can be obtained by, for example, recrystallizing luliconazole using a short-chain alcohol that may contain water, filtering and drying by air blowing, measuring the amount of short-chain alcohol, and measuring the short-chain alcohol. If the amount is not in the preferred range, it can be produced by adding a short chain alcohol, if desired, such as by adding a short chain alcohol. Moreover, when there is too much short chain length alcohol, it can also adjust by carrying out ventilation drying further.
As recrystallization, recrystallization may be performed with hydrous alcohol, or water may be used as a poor solvent. The anti-solvent method is a method of adding a sufficient amount of water for precipitation to an alcohol solution containing luliconazole. As a preferred form, recrystallization with 10% hydrous alcohol is preferred in terms of final purity.
The recrystallization can be performed according to a normal recrystallization technique.
Such alcohol may be used together with water at the time of use, or may be used in a pre-hydrated state. The amount of water that can be used together is, for example, 9 to 80 with respect to the total amount of alcohol that may contain water. %, 30 to 80%, 50 to 75%, and a maximum of about 70% can be preferably exemplified.
＜２＞本発明の医薬原体用の組成物
本発明の医薬原体用の組成物は、ルリコナゾールと短鎖長のアルコール以外に、医薬原体として許容される範囲内の物質、不純物、異性体を含有することができるが、実質的にルリコナゾールと短鎖長アルコールからなる形態が特に好ましい。
<2> Composition for active pharmaceutical ingredient of the present invention The composition for active pharmaceutical ingredient of the present invention includes substances, impurities, and isomers within a range acceptable as an active pharmaceutical ingredient other than luliconazole and short-chain alcohol. However, a form consisting essentially of luliconazole and a short chain alcohol is particularly preferred.
斯くして得られた、本発明の結晶及び医薬原体用の組成物は、溶剤に対して優れた溶解性を有するため、溶解工程を含む製造工程を経て製造される、医薬製剤の製造において、異性体の生成などを抑制する作用を有する。この為、この様な医薬製剤の製造のための原料として用いることができる。 The thus-obtained composition for a crystal and drug substance of the present invention has excellent solubility in a solvent, and therefore, in the production of a pharmaceutical preparation produced through a production process including a dissolution process. , Has the effect of suppressing the formation of isomers. For this reason, it can be used as a raw material for the production of such a pharmaceutical preparation.
＜３＞本発明の医薬製剤
本発明の医薬製剤は、前記本発明の結晶又は医薬原体用の組成物を含有することを特徴とする。かかる結晶又は医薬原体用の組成物は、エタノール等の溶媒への溶解性に優れるため、溶解工程をその製造工程に含む製剤が好ましく、具体的には、溶液製剤、乳化製剤、液滴分散型の軟膏製剤などが好適に例示できる。特に、ルリコナゾールの含有量が５質量％を超える製剤は、溶解工程に時間を要するために、これを短縮する意味で好ましい。
ルリコナゾールの好ましい含有量は、製剤全量に対して０．１〜３０質量％であり、０
．５〜１５質量％がより好ましい。勿論、錠剤などの経口投与剤に加工した場合においても、溶解速度、物理的安定性に優れるために好ましく、この様な経口投与製剤も本発明の製剤に属する。
製剤におけるルリコナゾールの含有量、処理条件等にもよるが、例えばルリコナゾールの含有量が製剤全量に対して０．１〜３０質量％である製剤を調製する際の溶解工程において、本発明の結晶又は医薬原体用の組成物を用いた場合の溶解工程に要する時間は、従来使用されるルリコナゾールを用いた場合の溶解工程に要する時間の８０％以下、好ましくは７５％以下、より好ましくは７０％以下であり得る。
本発明の製剤には、本発明の結晶又は医薬原体用の組成物以外に、溶剤、着色剤、抗酸化剤、キレート剤、乳化・分散剤、可溶化剤、崩壊剤、賦形剤、結合剤、被覆剤、矯味矯臭剤等を適宜加えて、常法に従って処理することにより製造できる。
斯くして得られた本発明のルリコナゾール製剤は、ルリコナゾール製造直後の初期値において、異性体量が抑制されていることを特徴とする。ルリコナゾール製造直後の初期値において、異性体（ＳＥ体、Ｚ体）量が、従来のｎ−ヘキサン・酢酸エチルから再結晶する方法により製造された（１１−１）面を特異的な成長面とする晶癖を有する結晶を用いた場合に対して、例えば、ＳＥ体であれば８０％以下、好ましくは７０％以下、より好ましくは６０％以下であり、Ｚ体であれば７０％以下、好ましくは６０％以下、より好ましくは５０％以下であり、ＳＥ体とＺ体の和であれば、８０％以下、好ましくは７０％以下、より好ましくは６０％以下でありうる。
特に、溶剤への溶解工程においては前記異性体が発生する可能性が高いので、この様な工程を含んで製造される医薬製剤の原体として、本発明の結晶又は医薬原体用の組成物は特に好適である。
<3> Pharmaceutical Formulation of the Present Invention The pharmaceutical formulation of the present invention is characterized by containing the composition for a crystal or drug substance of the present invention. Since such a composition for a crystal or drug substance is excellent in solubility in a solvent such as ethanol, a preparation including a dissolution step in its production process is preferable. Specifically, a solution preparation, an emulsion preparation, a droplet dispersion Suitable examples include mold ointment preparations. In particular, a preparation in which the content of luliconazole exceeds 5% by mass is preferable in terms of shortening this because it takes time for the dissolution process.
The preferable content of luliconazole is 0.1 to 30% by mass with respect to the total amount of the preparation,
. 5-15 mass% is more preferable. Of course, even when processed into an oral preparation such as a tablet, it is preferable because of its excellent dissolution rate and physical stability. Such an oral preparation also belongs to the preparation of the present invention.
Depending on the content of luliconazole in the preparation, the processing conditions, etc., for example, in the dissolution step when preparing a preparation in which the content of luliconazole is 0.1 to 30% by mass relative to the total amount of the preparation, The time required for the dissolution process when using the composition for the drug substance is 80% or less, preferably 75% or less, more preferably 70% of the time required for the dissolution process when using the conventionally used luliconazole. It can be:
In addition to the composition for the crystal or drug substance of the present invention, the preparation of the present invention includes a solvent, a colorant, an antioxidant, a chelating agent, an emulsifying / dispersing agent, a solubilizer, a disintegrant, an excipient, It can manufacture by adding a binder, a coating agent, a flavoring agent, etc. suitably, and processing according to a conventional method.
The thus obtained luliconazole preparation of the present invention is characterized in that the amount of isomers is suppressed at the initial value immediately after the production of luliconazole. In the initial value immediately after the production of luliconazole, the (11-1) plane in which the amount of isomers (SE-form, Z-form) is produced by recrystallization from conventional n-hexane / ethyl acetate is defined as a specific growth plane. For example, in the case of using a crystal having a crystal habit, the SE body is 80% or less, preferably 70% or less, more preferably 60% or less, and the Z body is 70% or less, preferably Is 60% or less, more preferably 50% or less, and the sum of SE body and Z body may be 80% or less, preferably 70% or less, more preferably 60% or less.
In particular, since the isomer is highly likely to be generated in the dissolution step in a solvent, the crystalline or pharmaceutical active ingredient composition of the present invention is used as the original pharmaceutical preparation produced by including such a step. Is particularly preferred.
本発明の医薬製剤又は医薬組成物は、ルリコナゾールの特性を利用し、真菌による疾病の治療又は悪化の予防に用いることが好ましい。また、トリコモナス属等の原虫による疾病の治療又は悪化の予防に用いることも好ましい。真菌による疾病としては、水虫のような足部白癬症、カンジダ、デンプウのような体部白癬症、爪白癬のようなハードケラチン部分の白癬症が例示でき、その効果が顕著なことから、爪白癬のようなハードケラチン部分の処置に用いることが特に好ましい。本発明の医薬組成物の効果は爪に特に好適に発現されるが、通常の皮膚真菌症にも及ぶので、本発明の構成を充足する皮膚真菌症に対する医薬組成物も本発明の技術的範囲に属する。この様な皮膚真菌症としては、足白癬症や足白癬症の内、かかとなどに現れる角質増殖型の白癬症などが例示できる。上記皮膚真菌症においては、通常の薬剤が効果を奏しにくい角質増殖型の白癬症への適用が本発明の効果が著しく現れるので好ましい。 The pharmaceutical preparation or pharmaceutical composition of the present invention is preferably used for the treatment of diseases caused by fungi or prevention of deterioration by utilizing the characteristics of luliconazole. Moreover, it is also preferable to use it for treatment of diseases caused by protozoa such as Trichomonas or prevention of deterioration. Examples of fungal diseases include foot ringworms such as athlete's foot, body ringworms such as Candida and Denpu, and hard keratinous ringworm such as onychomycosis. It is particularly preferred for use in the treatment of hard keratin moieties such as ringworm. The effect of the pharmaceutical composition of the present invention is particularly suitably expressed in the nail, but also extends to normal dermatomycosis, so that the pharmaceutical composition for dermatomycosis satisfying the constitution of the present invention is also within the technical scope of the present invention. Belonging to. Examples of such dermatomycosis include keratoproliferative type ringworm that appears on the heel of foot tinea and tinea pedis. In the above dermatomycosis, the application of the present invention to keratoproliferative type tinea which is difficult to achieve an effect is preferable since the effect of the present invention is remarkably exhibited.
その使用態様は、患者の体重、年令、性別、症状等を考慮して適宜選択できるが、通常成人の場合、ルリコナゾールを１日当たり０．０１〜１ｇ投与するのが好ましい。また、真菌による疾病に通常使用されているルリコナゾールの使用量を参考にすることができる。
例えば外用剤であれば、一日に一回又は数回、疾病の箇所に適量を塗布することが例示でき、かかる処置は連日行われることが好ましい。特に、爪白癬に対しては、通常の製剤では為し得ない量の有効成分であるルリコナゾールを、爪内に移行せしめることが出来る。これにより、長期間抗真菌剤を飲用することなく、外用のみによって爪白癬を治療することが出来る。又、再発や再感染が爪白癬では大きな問題となっているが、本発明の医薬組成物を、症状鎮静後１〜２週間投与することにより、この様な再発や再感染を防ぐことができる。この様な形態で本発明の医薬組成物は予防効果を奏する。
The mode of use can be appropriately selected in consideration of the patient's weight, age, sex, symptoms, etc. In general, for adults, it is preferable to administer 0.01 to 1 g of luliconazole per day. Moreover, the usage-amount of luliconazole normally used for the disease by fungi can be referred.
For example, in the case of an external preparation, an appropriate amount can be applied to the site of the disease once or several times a day, and such treatment is preferably performed every day. Particularly for onychomycosis, luliconazole, which is an active ingredient in an amount that cannot be achieved with conventional preparations, can be transferred into the nail. Thereby, it is possible to treat onychomycosis only by external use without taking an antifungal agent for a long time. In addition, recurrence and reinfection are a major problem in onychomycosis, but such recurrence and reinfection can be prevented by administering the pharmaceutical composition of the present invention for 1 to 2 weeks after sedation of symptoms. . In such a form, the pharmaceutical composition of the present invention has a preventive effect.
以下に、実施例を示して本発明について更に詳細に説明を加えるが、本発明は以下の実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples.
＜参考例１＞
酢酸エチル・ｎ−ヘキサン混液から再結晶し得られたルリコナゾールを用いて、これを１０％含水エタノールから再結晶し、濾取して、五酸化リンを入れたデシケータで乾燥させた。このもののエタノール含有量を、ガスクロマトグラフで測定したところ、３，５００ｐｐｍであり、エタノールを含有していたので、このものを参考例の結晶（結晶１）であると確認した。尚、参考例の結晶の原料となった、酢酸エチル・ｎ−ヘキサンから再結晶し得られたルリコナゾール（原料１）のエタノールの含有量は、検知限度以下であった。
<Reference Example 1>
This was recrystallized from 10% aqueous ethanol using luliconazole obtained by recrystallization from an ethyl acetate / n-hexane mixture, filtered, and dried in a desiccator containing phosphorus pentoxide. The ethanol content of this product was measured with a gas chromatograph and found to be 3,500 ppm. Since it contained ethanol, this product was confirmed to be the crystal of Reference Example (Crystal 1). In addition, the ethanol content of luliconazole (raw material 1) obtained by recrystallization from ethyl acetate / n-hexane, which was a raw material for the crystal of the reference example, was below the detection limit.
参考例の結晶１について、単結晶Ｘ線構造解析（装置機種名：ＲＵ−Ｈ２Ｒ、製造会社名：リガク、条件：Ｘ線源：ＣｕＫα、測定温度：２６℃、管電圧：５０ｋＶ、管電流：１８０ｍＡ、２θｍａｘ:１５０．０°構造解析法：直接法（ＳＨＥＬＸ８６））を行っ
た。測定値より求められた結晶系、空間群、格子定数及びＲ因子は次の通りであった。
About crystal 1 of the reference example, single crystal X-ray structure analysis (apparatus model name: RU-H2R, manufacturer name: Rigaku, condition: X-ray source: CuKα, measurement temperature: 26 ° C., tube voltage: 50 kV, tube current: 180 mA, 2θmax: 150.0 ° Structural analysis method: direct method (SHELX86)) was performed. The crystal system, space group, lattice constant and R factor determined from the measured values were as follows.
結晶系：単斜晶
空間群：Ｐ２1
格子定数
ａ＝９．０１７１（９）Å
ｂ＝８．１６７（１）Å
ｃ＝１０．８７８（１）Å
β＝９５．９１７（９）°
Ｒ因子
Ｒ＝０．０４６
Ｒw＝０．０４７
Crystal system: Monoclinic space group: P2 1
Lattice constant a = 9.0171 (9) Å
b = 8.167 (1) Å
c = 10.878 (1) Å
β = 95.917 (9) °
R factor R = 0.046
R w = 0.047
＜参考例２＞
参考例１の原料１（比較例の結晶）と結晶１について、溶出試験（攪拌条件：５０ｒｐｍ）を行い、溶出動態を調べた。全ての結晶が溶解したのを確認した後、溶液中に生成した異性体であるＺ体とＳＥ体をＨＰＬＣで分析・定量した。
溶出試験は、溶媒として５００ｍＬの無水エタノールを用い、１ｇのサンプルを攪拌下室温で溶解せしめ、溶解に要した時間も同時に測定した。結果を表１に示す。これより、結晶１は溶解に要する時間が短く、以て、溶解工程において異性体であるＺ体とＳＥ体の生成が抑制されていることが判る。
なお、ＨＰＬＣの条件は、カラム；ＣＨＩＲＡＬＣＥＬ ＯＤ−ＲＨ ４．６×１５０ｍｍ、カラム温度；３５℃、移動相；メタノール／２％ヘキサフルオロリン酸カリウム水溶液の混液（８５：１５、ｖ／ｖ）、流速；０．６ｍＬ／ｍｉｎ．、検知；２９５ｎｍ）であった。
<Reference Example 2>
A dissolution test (stirring condition: 50 rpm) was performed on the raw material 1 (crystal of comparative example) and the crystal 1 of Reference Example 1 to examine dissolution kinetics. After confirming that all the crystals were dissolved, the Z-form and SE-form, which are isomers formed in the solution, were analyzed and quantified by HPLC.
In the dissolution test, 500 mL of absolute ethanol was used as a solvent, 1 g of a sample was dissolved at room temperature with stirring, and the time required for dissolution was also measured. The results are shown in Table 1. From this, it can be seen that the time required for the dissolution of the crystal 1 is short, and thus the formation of the Z isomer and SE isomer, which are isomers, is suppressed in the dissolution process.
The HPLC conditions were as follows: column: CHIRALCEL OD-RH 4.6 × 150 mm, column temperature: 35 ° C., mobile phase: mixed liquid of methanol / 2% aqueous potassium hexafluorophosphate (85:15, v / v), Flow rate: 0.6 mL / min. , Detection; 295 nm).
＜参考例３＞
参考例１の再結晶条件を変えて、得られた結晶（結晶２，３）のアルコール含有量を測定し、併せて、エタノールへの溶け具合も肉眼で観察した。結果を表２に示す。結晶２、結晶３は参考例の結晶であり、溶状も良好であった。即ち、１，０００ｐｐｍ以上のエタノールを含有することにより、特に溶解性が向上することが判る。
<Reference Example 3>
The recrystallization conditions of Reference Example 1 were changed, and the alcohol content of the obtained crystals (crystals 2 and 3) was measured. At the same time, the solubility in ethanol was also observed with the naked eye. The results are shown in Table 2. Crystals 2 and 3 were the crystals of the reference example, and the solubility was also good. That is, it can be seen that the solubility is particularly improved by containing 1,000 ppm or more of ethanol.
＜参考例４＞
参考例の結晶１を用いて、医薬製剤（ローション製剤）を作製した。即ち、処方成分を加熱し、攪拌、可溶化し、可溶化を確認後、速やかに攪拌冷却し、本発明の医薬製剤を得た。溶解に要した時間は、５分以下であった。このものについて、Ｚ体とＳＥ体とを計測した。Ｚ体の含有量は検知限度以下、ＳＥ体は０．０３％であり、安定性を損なわずに製造できたことが確認された。
<Reference Example 4>
A pharmaceutical preparation (lotion preparation) was prepared using Crystal 1 of Reference Example. That is, the prescription ingredients were heated, stirred and solubilized, and after confirming solubilization, they were rapidly stirred and cooled to obtain the pharmaceutical preparation of the present invention. The time required for dissolution was 5 minutes or less. About this thing, Z body and SE body were measured. The Z-form content was below the detection limit and the SE-form was 0.03%, confirming that it could be produced without impairing stability.
＜参考例５＞
参考例１の再結晶条件を変えて得られた結晶４のアルコール含量を測定し、併せて、エタノールへの溶け具合を、参考例１の比較例の結晶及び結晶３と比較して溶解性を比較した。
尚、結晶４は以下のように調製した。即ち、ルリコナゾール５ｇに１５０ｍＬのエタノールを加え、還流して可溶化し、攪拌しながらゆっくり７０℃まで冷却し、この温度で２０分保持した後、これに水２０ｍＬを加え、攪拌冷却し、析出した結晶を濾取して、３０℃で送風しながら４８時間乾燥させて、参考例の結晶４を得た。このもののエタノールの含有量は２６２ｐｐｍであった。溶解性は、比較例＜＜結晶４＜結晶３であり、結晶４であっても、本発明の結晶の効果を奏していることがわかる。これより、許容されるアルコールの下限値は１００ｐｐｍと推測された。
<Reference Example 5>
The alcohol content of the crystal 4 obtained by changing the recrystallization conditions in Reference Example 1 was measured, and the solubility in ethanol was also compared with that of the Comparative Example Crystal of Reference Example 1 and Crystal 3 in combination. Compared.
Crystal 4 was prepared as follows. That is, 150 mL of ethanol was added to 5 g of luliconazole, solubilized by refluxing, slowly cooled to 70 ° C. with stirring, held at this temperature for 20 minutes, then added with 20 mL of water, cooled with stirring, and precipitated. The crystals were collected by filtration and dried for 48 hours while blowing air at 30 ° C. to obtain Crystal 4 of Reference Example. The ethanol content of this product was 262 ppm. The solubility is Comparative Example << Crystal 4 <Crystal 3 and it can be seen that even Crystal 4 has the effect of the crystal of the present invention. From this, the lower limit of the allowable alcohol was estimated to be 100 ppm.
＜参考例６＞
参考例１の再結晶条件を変えて得られた結晶５のアルコール含量を測定し、併せて、エタノールへの溶け具合を、参考例１の比較例の結晶及び結晶２と比較して溶解性を比較した。
尚、結晶５は以下のように調製した。即ち、ルリコナゾール５ｇに１５０ｍＬのエタノールを加え、還流して、可溶化し、攪拌しながらゆっくり８０℃まで冷却し、この温度で５分間保持し、これに水１５ｍＬを徐々に加え、攪拌冷却し、析出した結晶を濾取して、３０℃で送風しながら２４時間乾燥させて、参考例の結晶５を得た。この結晶のエタノールの含有量は７０２９ｐｐｍであった。溶解性は、比較例の結晶＜＜結晶２＝結晶５であった。
<Reference Example 6>
The alcohol content of the crystal 5 obtained by changing the recrystallization conditions of Reference Example 1 was measured, and the solubility in ethanol was also compared with that of the Comparative Example Crystal of Reference Example 1 and Crystal 2 in combination. Compared.
Crystal 5 was prepared as follows. That is, 150 mL of ethanol was added to 5 g of luliconazole, refluxed, solubilized, slowly cooled to 80 ° C. while stirring, held at this temperature for 5 minutes, and 15 mL of water was gradually added thereto, stirred and cooled, The precipitated crystals were collected by filtration and dried for 24 hours while blowing air at 30 ° C. to obtain Reference Example Crystal 5. The ethanol content of the crystals was 7029 ppm. The solubility was the crystal of the comparative example << crystal 2 = crystal 5.
＜参考例７＞
参考例１の再結晶条件を変えて得られた結晶６のアルコール含量を測定し、併せて、エタノールへの溶け具合を、参考例１の比較例の結晶、結晶４及び結晶３と比較して溶解性を比較した。
尚、結晶６は以下のように調製した。即ち、ルリコナゾール５ｇに２００ｍＬのエタノールを加え、還流して可溶化し、攪拌しながらゆっくり７０℃まで冷却し、この温度で１０分保持した後、これに水１０ｍＬを加え、攪拌冷却し、更に水１０ｍＬを加え、析出した結晶を濾取して、３０℃で送風しながら４８時間乾燥させて、参考例の結晶６を得た。結晶６のエタノール含有量は、４０３ｐｐｍであった。溶解性は、比較例の結晶＜＜結晶４＝結晶６＜結晶３の順であった。
<Reference Example 7>
The alcohol content of the crystal 6 obtained by changing the recrystallization conditions of Reference Example 1 was measured, and the solubility in ethanol was also compared with the crystals of Comparative Example, Crystal 4 and Crystal 3 of Reference Example 1. Solubility was compared.
Crystal 6 was prepared as follows. That is, 200 mL of ethanol was added to 5 g of luliconazole, solubilized by refluxing, slowly cooled to 70 ° C. with stirring, held at this temperature for 10 minutes, then added with 10 mL of water, cooled with stirring, and further cooled with water. 10 mL was added, and the precipitated crystals were collected by filtration and dried for 48 hours while blowing air at 30 ° C. to obtain Crystal 6 of Reference Example. The ethanol content of the crystal 6 was 403 ppm. The solubility was in the order of crystal of comparative example << crystal 4 = crystal 6 <crystal 3.
＜参考例８＞
参考例１の再結晶条件を変えて得られた結晶７のアルコール含量を測定し、併せて、エタノールへの溶け具合を、参考例１の比較例の結晶及び結晶５と比較して溶解性を比較した。尚、結晶７は以下のように調製した。即ち、ルリコナゾール５ｇに２００ｍＬの９０
％エタノール水溶液を加え、還流して、可溶化し、攪拌しながらゆっくり８０℃まで冷却し、この温度で５分間保持し、これに水１５ｍＬを徐々に加え、攪拌冷却し、析出した結晶を濾取して、３０℃で送風しながら２４時間乾燥させて、参考例の結晶７を得た。この結晶のエタノールの含有量は４１４６ｐｐｍであった。溶解性は比較例の結晶＜＜結晶５＝結晶７であった。
<Reference Example 8>
The alcohol content of the crystal 7 obtained by changing the recrystallization conditions in Reference Example 1 was measured, and the solubility in ethanol was also compared with the crystals of Comparative Example 1 and Crystal 5 of Reference Example 1 in terms of solubility. Compared. Crystal 7 was prepared as follows. That is, 200 mL of 90 mL of 5 g of luliconazole
% Ethanol aqueous solution was added, refluxed, solubilized, slowly cooled to 80 ° C. with stirring, held at this temperature for 5 minutes, 15 mL of water was gradually added thereto, stirred and cooled, and the precipitated crystals were filtered. And dried for 24 hours while blowing air at 30 ° C. to obtain Crystal 7 of Reference Example. The ethanol content of the crystals was 4146 ppm. The solubility was the crystal of the comparative example << crystal 5 = crystal 7.
参考例１、３、５〜７の結果を見ると高温時に貧溶媒を加え、貧溶媒法で再結晶することにより、本発明の結晶の内、アルコール含量が高いものが得られることが判る（参考例６）。また、貧溶媒の添加の衝撃を和らげるとアルコール含量が高くなる傾向にあることも判る（参考例８）。水含量の多いアルコール・水混合溶媒より再結晶する場合、或いは、低温で貧溶媒を加え再結晶させる場合はアルコール含有量が下限値に近くなることも判る（参考例５、７）。 From the results of Reference Examples 1, 3, and 5 to 7, it can be seen that by adding a poor solvent at a high temperature and recrystallizing by the poor solvent method, a crystal having a high alcohol content can be obtained among the crystals of the present invention ( Reference example 6). It can also be seen that the alcohol content tends to increase when the impact of the addition of the poor solvent is reduced (Reference Example 8). It can also be seen that when recrystallizing from an alcohol / water mixed solvent having a high water content, or when recrystallizing by adding a poor solvent at a low temperature, the alcohol content approaches the lower limit (Reference Examples 5 and 7).
＜参考例９＞
結晶５〜７及び比較例の結晶について、参考例２の方法に基づいて溶解性を調べた（攪拌条件：２００ｒｐｍ）。溶解に要した時間を図１に示す。これよりこれらの結晶は何れも比較例に比して溶解性に優れることが判る。
<Reference Example 9>
About the crystal | crystallization 5-7 and the crystal | crystallization of a comparative example, solubility was investigated based on the method of the reference example 2 (stirring conditions: 200 rpm). The time required for dissolution is shown in FIG. From this, it can be seen that these crystals are all excellent in solubility as compared with the comparative example.
＜実施例１＞
参考例１の再結晶条件を変えて、得られた組成物のアルコール含有量（再結晶に用いたアルコールの含有量）を測定し、併せて、エタノールへの溶け具合も肉眼で観察した。結果を表４に示す。尚、再結晶は、結晶８については、１０ｇのルリコナゾールに１５０ｍＬのメタノールを加え、６０℃で加温し、攪拌下溶解させ、７０℃に加温した水５０ｍＬを加え、攪拌混合したのち、５℃の冷却水で攪拌しながら、結晶を析出させ、３０分間静置したのち、濾取し、４０℃で４８時間送風乾燥して調製した。結晶９については、１０ｇのルリコナゾールに５０ｍＬのメタノールを加え、水１５０ｍＬを加えること以外は、上記と同様に再結晶を行った。結晶１０については、１０ｇのルリコナゾールに１００ｍＬのメタノールを加え、水１００ｍＬを加えること以外は、上記と同様に再結晶を行った。結晶１１については、１０ｇのルリコナゾールに２００ｍＬの２-プロパノールを加え
、水を加えないこと以外は、上記と同様に再結晶を行った。これらの結晶は、溶状も良好であった。即ち、５００ｐｐｍ以上、さらに好ましくは１０００ｐｐｍ以上の炭素数１〜４のアルコールを含有することにより、特に溶解性が向上することが判る。
<Example 1>
The recrystallization conditions of Reference Example 1 were changed, and the alcohol content (content of alcohol used for recrystallization) of the obtained composition was measured, and the degree of dissolution in ethanol was also observed with the naked eye. The results are shown in Table 4. In the recrystallization, for crystal 8, 150 mL of methanol was added to 10 g of luliconazole, heated at 60 ° C., dissolved with stirring, 50 mL of water heated to 70 ° C. was added, and the mixture was stirred and mixed. Crystals were precipitated while stirring with cooling water at 0 ° C., allowed to stand for 30 minutes, then collected by filtration and dried by blowing at 40 ° C. for 48 hours. Crystal 9 was recrystallized in the same manner as described above except that 50 mL of methanol was added to 10 g of luliconazole and 150 mL of water was added. For crystal 10, recrystallization was carried out in the same manner as above except that 100 mL of methanol was added to 10 g of luliconazole and 100 mL of water was added. For crystal 11, recrystallization was carried out in the same manner as above except that 200 mL of 2-propanol was added to 10 g of luliconazole and no water was added. These crystals were also good in solution. That is, it can be seen that the solubility is particularly improved by containing an alcohol having 1 to 4 carbon atoms of 500 ppm or more, more preferably 1000 ppm or more.
＜実施例２＞
結晶１０と参考例１の結晶１とは、粉末Ｘ線回折測定（２θ：５〜３５°）の回折ピークはいずれも一致し、結晶系は同一である。すなわち、結晶１０の単結晶Ｘ線構造解析の測定値より求められる結晶系、空間群、格子定数及びＲ因子は、参考例１の結晶１と同じく、次の通りである。
<Example 2>
The crystal 10 and the crystal 1 of Reference Example 1 all have the same diffraction peak in powder X-ray diffraction measurement (2θ: 5 to 35 °), and the crystal system is the same. That is, the crystal system, space group, lattice constant, and R factor obtained from the measured values of the single crystal X-ray structure analysis of the crystal 10 are as follows, similar to the crystal 1 of Reference Example 1.
結晶系：単斜晶
空間群：Ｐ２1
格子定数
ａ＝９．０１７１（９）Å
ｂ＝８．１６７（１）Å
ｃ＝１０．８７８（１）Å
β＝９５．９１７（９）°
Ｒ因子
Ｒ＝０．０４６
Ｒw＝０．０４７
Crystal system: Monoclinic space group: P2 1
Lattice constant a = 9.0171 (9) Å
b = 8.167 (1) Å
c = 10.878 (1) Å
β = 95.917 (9) °
R factor R = 0.046
R w = 0.047
＜実施例３＞
結晶１０を用いて、アルコールを含有する原体の効果を確かめた。比較例としてはアルコールを全く含有しないｎ−ヘキサン・酢酸エチル混液から再結晶して得られた結晶（比較結晶）を用いた。Ｔｒｉｃｈｏｍｏｎａｓ Ｖａｇｉｎａｌｉｓ（トリコモナス・ヴァージナリス；臨床分離株）を用いて、ルリコナゾールの直接効果を調べた。即ち、「トリコモナス培地Ｆ」（富士製薬製）に比較結晶を５．０８ｍｇを入れたものと、結晶１０を５．０８ｍｇを入れたものと、水５μＬ（対照）を入れたものを用意し、これに３．９３×１０5個／ｍＬのトリコモナス・ヴァージナリスの培養液２００ｍＬを加え、３７℃で
４日間培養し、血球計数板上でトリコモナスの個数を計数した。結果を表５に示す。これら３つのサンプル間には、危険率１％以下で有意差が認められた。これより、本発明の結晶は抗原虫作用に優れることがわかる。
<Example 3>
Crystal 10 was used to confirm the effect of the drug substance containing alcohol. As a comparative example, a crystal (comparative crystal) obtained by recrystallization from an n-hexane / ethyl acetate mixed solution containing no alcohol was used. The direct effect of luliconazole was examined using Trichomonas Vaginalis (Trichomonas virginalis; clinical isolate). That is, prepare "Trichomonas medium F" (manufactured by Fuji Pharmaceutical) with 5.08 mg of comparative crystals, 5.08 mg of crystals 10 and 5 μL of water (control). To this, 200 mL of a culture solution of 3.93 × 10 5 cells / mL Trichomonas virginalis was added, followed by culturing at 37 ° C. for 4 days, and the number of Trichomonas was counted on a hemocytometer. The results are shown in Table 5. A significant difference was observed between these three samples with a risk rate of 1% or less. This shows that the crystal of the present invention is excellent in antiprotozoal action.
＜実施例４＞
下記表６に示す処方に従って、錠剤を作製し、硬度を計測した。硬度計はＰＴＢ３１１（Ｐｈａｒｍａ Ｔｅｓｔ ＧｍｂＨ製）を用いた。打錠条件は、９ｍｍφの臼と杵を用いて打錠圧１ｔｏｎ／ｃｍ2で行った。比較例は比較結晶を用いて、同様に作業して行っ
た。６個の平均を表７に示す。これより、本発明の結晶は硬度が高く、物理的安定性に優れることがわかる。即ち、アルコールを含有する原体は、原体同士の親和力が強いために、硬度の高い錠剤が得られるものと推定される。
<Example 4>
Tablets were prepared according to the formulation shown in Table 6 below, and the hardness was measured. As the hardness meter, PTB311 (manufactured by Pharma Test GmbH) was used. Tableting conditions were performed using a 9 mmφ mortar and scissors at a tableting pressure of 1 ton / cm 2 . The comparative example was carried out in the same manner using a comparative crystal. The average of 6 is shown in Table 7. From this, it can be seen that the crystal of the present invention has high hardness and excellent physical stability. That is, since the active ingredient containing alcohol has a strong affinity between the active ingredients, it is estimated that a tablet with high hardness can be obtained.
本発明は、医薬に応用できる。 The present invention can be applied to medicine.
Claims (5)
下記に示すルリコナゾールと、結晶全量に対して、１００〜１０，０００ｐｐｍの含有量のメタノールからなり、
結晶系が単斜晶、空間群がＰ２ 1 、格子定数がａ＝９．０１７１（９）Å、ｂ＝８．１
６７（１）Å、ｃ＝１０．８７８（１）Å、β＝９５．９１７（９）°、Ｒ因子がＲ＝０．０４６、Ｒ w ＝０．０４７である結晶複合体。
And luliconazole shown below, relative to the crystal total amount, Ri Do from the content of methanol 100 to 10,000 ppm,
The crystal system is monoclinic, the space group is P2 1 , the lattice constant is a = 9.0171 (9) Å, b = 8.1
67 (1) Å, c = 10.878 (1) Å, β = 95.917 (9) °, R factor R = 0.046, R w = 0.047 der Ru crystalline complex.
る工程を含む、医薬製剤の製造方法。 A method for producing a pharmaceutical preparation, comprising a step of dissolving the crystal complex according to claim 1 or the composition for a drug substance according to claim 2 in a solvent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014029418A JP5698395B2 (en) | 2013-06-24 | 2014-02-19 | Crystal and pharmaceutical preparation containing the crystal |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013131504 | 2013-06-24 | ||
| JP2013131504 | 2013-06-24 | ||
| WOPCT/JP2013/074775 | 2013-09-06 | ||
| PCT/JP2013/074775 WO2014042231A1 (en) | 2012-09-14 | 2013-09-06 | Crystal and pharmaceutical preparation containing the same crystal |
| JP2014029418A JP5698395B2 (en) | 2013-06-24 | 2014-02-19 | Crystal and pharmaceutical preparation containing the crystal |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015024899A Division JP5795694B2 (en) | 2013-06-24 | 2015-02-12 | Crystal and pharmaceutical preparation containing the crystal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015027983A JP2015027983A (en) | 2015-02-12 |
| JP5698395B2 true JP5698395B2 (en) | 2015-04-08 |
Family
ID=52491964
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014029418A Active JP5698395B2 (en) | 2013-06-24 | 2014-02-19 | Crystal and pharmaceutical preparation containing the crystal |
| JP2014029419A Active JP5699234B2 (en) | 2013-06-24 | 2014-02-19 | Crystal and pharmaceutical preparation containing the crystal |
| JP2015024899A Active JP5795694B2 (en) | 2013-06-24 | 2015-02-12 | Crystal and pharmaceutical preparation containing the crystal |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014029419A Active JP5699234B2 (en) | 2013-06-24 | 2014-02-19 | Crystal and pharmaceutical preparation containing the crystal |
| JP2015024899A Active JP5795694B2 (en) | 2013-06-24 | 2015-02-12 | Crystal and pharmaceutical preparation containing the crystal |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP5698395B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017101009A (en) | 2015-12-04 | 2017-06-08 | 株式会社ポーラファルマ | Anti-acanthamoeba agent and method for producing the same |
| WO2018179170A1 (en) * | 2017-03-29 | 2018-10-04 | 日本農薬株式会社 | Pharmaceutical composition for treatment of infection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3278738B2 (en) * | 1995-07-08 | 2002-04-30 | 日本農薬株式会社 | Antifungal agent |
| US20100204293A1 (en) * | 2007-09-05 | 2010-08-12 | Pola Pharma Inc. | Pharmaceutical composition |
| CN103012385B (en) * | 2012-02-17 | 2015-07-08 | 山东威智医药工业有限公司 | Crystal form of luliconazole and preparation method thereof |
-
2014
- 2014-02-19 JP JP2014029418A patent/JP5698395B2/en active Active
- 2014-02-19 JP JP2014029419A patent/JP5699234B2/en active Active
-
2015
- 2015-02-12 JP JP2015024899A patent/JP5795694B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015091890A (en) | 2015-05-14 |
| JP5795694B2 (en) | 2015-10-14 |
| JP2015027984A (en) | 2015-02-12 |
| JP5699234B2 (en) | 2015-04-08 |
| JP2015027983A (en) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5589130B1 (en) | Crystal and pharmaceutical preparation containing the crystal | |
| JP5453559B1 (en) | Crystal having crystal habit and pharmaceutical composition obtained by processing the crystal | |
| EP2964641B1 (en) | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | |
| JP2011516430A (en) | Rubiprostone crystal, production method and use thereof | |
| JP5587488B1 (en) | Evaluation method and index substance of preparation containing luliconazole | |
| JP5795694B2 (en) | Crystal and pharmaceutical preparation containing the crystal | |
| AU2016269359B2 (en) | Sodium salt of uric acid transporter inhibitor and crystalline form thereof | |
| JP5680161B1 (en) | Crystal having crystal habit and pharmaceutical composition containing the crystal as an active ingredient | |
| JP5795693B2 (en) | Crystal having crystal habit and pharmaceutical composition containing the crystal as an active ingredient | |
| KR20170066196A (en) | Anti-acanthamoeba agent and method for producing the same | |
| CN104447683A (en) | Stable Bilastine compound | |
| JP5623671B1 (en) | Evaluation method and index substance of preparation containing luliconazole | |
| KR20180098104A (en) | Composition for alleviating allergy comprising ethyl ferulate as an effective ingredient | |
| JP5926756B2 (en) | Evaluation method and index substance of preparation containing luliconazole | |
| JP2021001140A (en) | Method for producing stable azilsartan fine crystals | |
| JP2015113343A (en) | Evaluation method and index material of preparation containing luliconazole | |
| EP2653159A1 (en) | Bromfenac organic salts and preparation method, composition and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150120 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5698395 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |